BACKGROUND: The germ cell supranetwork multidisciplinary team (SMDT) for the Anglian Network covers a population of 7.5 million. METHODS: We reviewed 10 years of SMDT discussion and categorised them into five domains ((1) overall outcome, (2) chemotherapy regimens-untreated disease and salvage therapy, (3) radiology, (4) pathology and (5) complex cases) to assess the impact of the SMDT. RESULTS: A total of 2892 new cases were reviewed. In the first 5 years, patients with good prognosis disease had poorer survival in low-volume vs high-volume centres (87.8 vs 95.3, p = 0.02), but the difference was no longer significant in the last 5 years (93.3 vs 95.1, p = 0.30). Radiology review of 3206 scans led to rejection of the diagnosis of progression in 26 cases and a further 10 cases were down-staged. There were 790 pathology reviews by two specialised uropathologists, which lead to changes in 75 cases. 18F-fluorodeoxyglucose (18FDG) PET-CT was undertaken during this time period but did not help to predict who would have viable cancer. A total of 26 patients with significant mental health issues who were unable to give informed consent were discussed. CONCLUSION: SMDT working has led to an improvement in outcomes and refining of treatment in patients with germ cell tumours.
BACKGROUND: The germ cell supranetwork multidisciplinary team (SMDT) for the Anglian Network covers a population of 7.5 million. METHODS: We reviewed 10 years of SMDT discussion and categorised them into five domains ((1) overall outcome, (2) chemotherapy regimens-untreated disease and salvage therapy, (3) radiology, (4) pathology and (5) complex cases) to assess the impact of the SMDT. RESULTS: A total of 2892 new cases were reviewed. In the first 5 years, patients with good prognosis disease had poorer survival in low-volume vs high-volume centres (87.8 vs 95.3, p = 0.02), but the difference was no longer significant in the last 5 years (93.3 vs 95.1, p = 0.30). Radiology review of 3206 scans led to rejection of the diagnosis of progression in 26 cases and a further 10 cases were down-staged. There were 790 pathology reviews by two specialised uropathologists, which lead to changes in 75 cases. 18F-fluorodeoxyglucose (18FDG) PET-CT was undertaken during this time period but did not help to predict who would have viable cancer. A total of 26 patients with significant mental health issues who were unable to give informed consent were discussed. CONCLUSION:SMDT working has led to an improvement in outcomes and refining of treatment in patients with germ cell tumours.
Authors: T Tandstad; O Ståhl; O Dahl; H S Haugnes; U Håkansson; Å Karlsdottir; A Kjellman; C W Langberg; A Laurell; J Oldenburg; A Solberg; K Söderström; U Stierner; E Cavallin-Ståhl; R Wahlqvist; N Wall; G Cohn-Cedermark Journal: Ann Oncol Date: 2016-04-06 Impact factor: 32.976
Authors: C Albany; N Adra; A C Snavely; C Cary; T A Masterson; R S Foster; K Kesler; T M Ulbright; L Cheng; M Chovanec; F Taza; K Ku; M J Brames; N H Hanna; L H Einhorn Journal: Ann Oncol Date: 2018-02-01 Impact factor: 32.976
Authors: R de Wit; G Stoter; S B Kaye; D T Sleijfer; W G Jones; W W ten Bokkel Huinink; L A Rea; L Collette; R Sylvester Journal: J Clin Oncol Date: 1997-05 Impact factor: 44.544
Authors: F Honecker; J Aparicio; D Berney; J Beyer; C Bokemeyer; R Cathomas; N Clarke; G Cohn-Cedermark; G Daugaard; K-P Dieckmann; K Fizazi; S Fosså; J R Germa-Lluch; P Giannatempo; J A Gietema; S Gillessen; H S Haugnes; A Heidenreich; K Hemminki; R Huddart; M A S Jewett; F Joly; J Lauritsen; A Lorch; A Necchi; N Nicolai; C Oing; J Oldenburg; D Ondruš; A Papachristofilou; T Powles; A Sohaib; O Ståhl; T Tandstad; G Toner; A Horwich Journal: Ann Oncol Date: 2018-08-01 Impact factor: 32.976
Authors: Robert A Huddart; Rhian Gabe; Fay H Cafferty; Philip Pollock; Jeff D White; Jonathan Shamash; Michael H Cullen; Sally P Stenning Journal: Eur Urol Date: 2014-07-04 Impact factor: 20.096
Authors: Adriana Fonseca; João Lobo; Florette K Hazard; Joanna Gell; Peter K Nicholls; Robert S Weiss; Lindsay Klosterkemper; Samuel L Volchenboum; James C Nicholson; A Lindsay Frazier; James F Amatruda; Aditya Bagrodia; Michelle Lockley; Matthew J Murray Journal: Br J Cancer Date: 2022-10-13 Impact factor: 9.075